Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

ºñ½ºÆ÷½ºÆ÷³×ÀÌÆ®·Î ÀÎÇÑ ÇÏ¾Ç ¹× »ó¾Ç°ñ¿¡ ¹ß»ýÇÑ °ñ±«»ç¿¡ ´ëÇÑ ÀÓ»óÀû ¿¬±¸

CLINICAL STUDY OF BISPHOSPHONATE-INDUCED OSTEONECROSIS OF MANDIBULAR AND MAXILLARY BONE

´ëÇѱ¸°­¾Ç¾È¸é¿Ü°úÇÐȸÁö 2009³â 35±Ç 5È£ p.353 ~ 360
Á¤Çý¸°, ±èÅ¿Ï, ÀÌÁ¤±Ù, ¼Û½ÂÀÏ,
¼Ò¼Ó »ó¼¼Á¤º¸
Á¤Çý¸° ( Joeng Hye-Rin ) - ¾ÆÁÖ´ëÇб³ ÀÇ°ú´ëÇÐ Ä¡°úÇб³½Ç
±èÅ¿Ϡ( Kim Tae-Wan ) - ¾ÆÁÖ´ëÇб³ ÀÇ°ú´ëÇÐ Ä¡°úÇб³½Ç
ÀÌÁ¤±Ù ( Lee Jeong-Keun ) - ¾ÆÁÖ´ëÇб³ ÀÇ°ú´ëÇÐ Ä¡°úÇб³½Ç
¼Û½ÂÀÏ ( Song Seung-Il ) - ¾ÆÁÖ´ëÇб³ ÀÇ°ú´ëÇÐ Ä¡°úÇб³½Ç

Abstract


Bisphosphonates are compounds widely used in the treatment of various metabolic and malignant bone disease. Recently, an association between bisphosphonate use and a rare dental condition termed ¡¯osteonecrosis of the jaw(ONJ)¡¯ has been reported. Bisphosphonate-related osteonecrosis of the jaw(BRONJ) is rare, but serious, side effect of bisphosphonate therapy in affected patients. It is characterized by poor wound healing and spontaneous intra-oral soft tissue break down, which lead to exposure of necrotic maxillary and mandibular bone. We reviewed 11 patients of BRONJ visited Ajou University Hospital Dental clinic from May 2007 to November 2008. The management of the patients included cessation of bisphosphonate therapy and various surgical restorative procedures and conservative care there after. Aggressive debridement is contraindicated. A new complication of bisphosphonate therapy administration, osteonecrosis of jaws, seems to be developing. The improved results after cessation of the medication should make clinicians reconsider the merits of the rampant use of bisphosphonates, while further investigation is needed to completely elucidate this complication

Å°¿öµå

BRONJ (Bisphosphonate-related osteonecrosis of the jaw);Osteonecrosis;Osteoporosis

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

   

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed